Skip to main content

Table 1 Patient *1 characteristics assessed based on smoking status and TP53-mutations

From: Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma

 

Total

Smokers*2

Non-smokers*2

p-value

MutantTP53

Wild-typeTP53

p-value

(N = 161: 69%)

(N = 71: 31%)

 

(N = 147: 63%)

(N = 87: 37%)

Smoking status – PYs

       

25%/50%/75%

0/25/40

25/40/46

0/0/0

<0.0001*3

8/30/40

0/20/40

0.085*3

Smokers – no. (%)

161 (69)

-

-

-

108 (74)

53 (61)

0.030*4

TP53-mutations – no. (%)

147 (63)

108 (67)*7

37 (52) *7

0.030*4

   

Age, years – yr. mean ± s.d.

63.2 ± 10.9

63.5 ± 10.2

62.6 ± 12.6

0.56*5

64.1 ± 10.4

61.6 ± 11.5

0.082*5

Men – no. (%)*6

187 (80)

152 (94)

33 (46)

<0.001*4

122 (83)

65 (75)

0.13*4

Drinking status – no. (%)*6

   

<0.001*4

  

0.043*4

Non-drinker

89 (38)

35 (22)

53 (75)

 

50 (34)

39 (45)

 

Moderate drinker

74 (32)

64 (40)

9 (13)

 

55 (37)

19 (22)

 

Heavy drinker

71 (30)

62 (39)

9 (13)

 

42 (29)

29 (33)

 

Primary site of tumor – no. (%)*6

   

0.030*4

  

0.13*4

Oropharyngea

63 (27)

47 (29)

16 (23)

 

37 (25)

26 (30)

 

Hypopharyngeal

64 (27)

47 (29)

16 (23)

 

49 (33)

15 (17)

 

Laryngeal

29 (12)

24 (15)

5 (7)

 

17 (12)

12 (14)

 

Oral

57 (24)

32 (20)

25 (35)

 

32 (22)

25 (29)

 

Nasal

21 (9)

11 (7)

9 (13)

 

12 (8)

9 (10)

 

Cell differentiation – no. (%)*6

   

0.023*4

  

0.94*4

Well differentiated

69 (31)

39 (25)

29 (43)

 

45 (31)

24 (29)

 

Moderately differentiated

111 (49)

84 (54)

26 (39)

 

70 (49)

41 (50)

 

Poorly differentiated

45 (20)

33 (21)

12 (18)

 

28 (20)

17 (21)

 

Stages – no. (%)*6

   

0.12*4

  

0.97*4

I

12 (5)

11 (7)

1 (1)

 

8 (5)

4 (5)

 

II

48 (21)

34 (21)

14 (20)

 

29 (20)

19 (22)

 

III

48 (21)

28 (18)

20 (29)

 

30 (21)

18 (21)

 

IV

124 (53)

87 (54)

35 (50)

 

79 (54)

45 (52)

 

Anticancer therapy – no. (%)

       

Radiotherapy ± Chemotherapy

27 (12)

22 (13)

4 (6)

0.13*4

15 (10)

12 (14)

0.41*4

CDKN2A-SCNAs – no. (%)*6

   

0.73*4

  

0.035*4

Norma

174 (77)

117 (76)

55 (80)

 

99 (72)

75 (86)

 

Heterozygous deletion

39 (17)

29 (19)

10 (14)

 

29 (21)

10 (11)

Homozygous deletion

12 (5)

8 (5)

4 (6)

 

10 (7)

2 (2)

 

p16 (+) – no. (%)

47 (20)

28 (17)

19 (27)

0.10*4

24 (16)

23 (26)

0.062*4

UGT2B17 CNVs – no. (%)*6

   

0.60*4

  

0.95*4

Homozygous deletions: 0 copy

181 (80)

124 (81)

55 (80)

 

111 (80)

70 (80)

 

Heterozygous deletion: 1 copy

42 (19)

28 (18)

14 (20)

 

26 (19)

16 (18)

 

Normal: 2 copies

2 (1)

2 (1)

0 (0)

0.60*4

1 (1)

1 (1)

0.95*4

  1. *1Smoking history was unavailable for two of the 234.
  2. *2Non-smokers were defined as having a <10-PYs history; smokers were defined as having a ≥10-PYs history.
  3. *3Mann-Whitney test was used to calculate the p-value.
  4. *4χ2 test was used to calculate the p-value. *5Student’s t test was used to calculate the --value.
  5. *6Because of rounding, total values are not always 100%. *7RR, 1.29; 95% CI, 1.00 to 1.65.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us